1165 EASTLAKE AVE E, SEATTLE, WA
Prices Upsized $300 Million Convertible Senior Notes Offering
Announces Planned Separation of Immune Medicine Businesses and Convertible Notes Offering
Shareholder Meeting Results; Election of Directors and Compensation Advisory
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Financial Results, Press Release
Announces Preliminary Fourth Quarter and Full Year 2025 Results
Other Events
Q1
FY 2024
Q3
Q2
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
Amended Registration Statement for Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities